Subhashis Banerjee, M.D.

Chief Medical Officer

Subhashis Banerjee, M.D., is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc. Prior to joining Artiva, Dr. Banerjee served as SVP of Clinical Development at VYNE Therapeutics Inc., where he led the clinical development of BET inhibitors across many immune-mediated conditions. Prior to that, he served as Vice President and Disease Area Head of Rheumatology and Dermatology at BMS, where he played a key role in the development strategy of immunology assets across multiple platforms for several immune-mediated diseases. During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu® (deucravacitinib), Orencia® (abatacept) and clazakizumab (anti-IL-6 antibody) for the treatment of a variety of rheumatology indications including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathy (IIM) and Sjögren’s Disease. Prior to working at BMS, Dr. Banerjee served as a global clinical program lead at Eli Lilly and Company on the clinical development of Taltz® (ixekizumab, anti-IL-17 antibody) in RA, psoriasis, psoriatic arthritis and ankylosing spondylitis that led to marketing authorizations in the latter three indications. Earlier in his career, Dr. Banerjee supported the clinical development of Xeljanz® (tofacitinib) at Pfizer Inc., and early development activities of Humira® (adalimumab) at AbbVie. Dr. Banerjee received his medical degree from Christian Medical College in Vellore, India, and he completed his residency in internal medicine at St. Vincent Hospital in Worcester, Massachusetts. He trained in immunology and autoimmune diseases at the Mayo Clinic and McGill University prior to joining the industry.